New combo therapy aims to fight tough pancreatic cancer
NCT ID NCT06821503
First seen Mar 13, 2026 · Last updated Jun 22, 2026 · Updated 11 times
Summary
This study tests a new drug called LM-108, given with an immunotherapy (penpulimab) and two chemotherapy drugs, in people with advanced pancreatic cancer. The goal is to see if the combination is safe and can shrink tumors or slow the disease. About 72 adults with advanced pancreatic cancer will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED PANCREATIC CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Cancer Hospital
RECRUITINGBeijing, Beijing Municipality, 100142, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Cancer Hospital Chinese Academy of Medical Science
NOT_YET_RECRUITINGBeijing, Beijing Municipality, 100021, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Chongqing Qeneral Hospital
NOT_YET_RECRUITINGChongqing, Chongqing Municipality, 400013, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Harbin Medical University Cancer Hospital
NOT_YET_RECRUITINGHarbin, Heilongjiang, 150081, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Huazhong University of Science and Technology Tongji Medical College of Huazhong University of Science and Technology
NOT_YET_RECRUITINGWuhan, Hubei, 430000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Jiangsu Cancer Hospital
NOT_YET_RECRUITINGNanjing, Jiangsu, 210000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Jiangsu Provincial People's Hospital
NOT_YET_RECRUITINGNanjing, Jiangsu, 210000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Peking Union Medical College Hospital
NOT_YET_RECRUITINGBeijing, Beijing Municipality, 100005, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First Affiliated Hospital of China Medical University
NOT_YET_RECRUITINGShenyang, Liaoning, 110000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First Affiliated Hospital of Nanchang University
NOT_YET_RECRUITINGNanchang, Jiangxi, 330006, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First Affiliated Hospital of Naval Medical University
NOT_YET_RECRUITINGShanghai, Shanghai Municipality, 200336, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First Affiliated Hospital of Xi'an Jiaotong University Medical College
NOT_YET_RECRUITINGXi'an, Shaanxi, 710000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First Affiliated Hospital of Zhengzhou University
NOT_YET_RECRUITINGZhengzhou, Henan, 450000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Sixth People's Hospital of Shenyang
NOT_YET_RECRUITINGShenyang, Liaoning, 110002, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Tianjin Cancer Hospital Airport Hospital
NOT_YET_RECRUITINGTianjin, Tianjin Municipality, 300000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Tianjin Medical University Cancer Institute & Hospital
NOT_YET_RECRUITINGTianjin, Tianjin Municipality, 300000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
LM-108 (a monoclonal antibody that clears certain immune cells) plus penpulimab (an immunotherapy) plus chemotherapy (albumin-bound paclitaxel and gemcitabine)
What this could lead to
If it works, this could point toward a new treatment option for advanced pancreatic cancer by combining immunotherapy with chemotherapy.
What could go wrong
This is an early-phase trial with only 72 participants, so results may not apply to all patients. The combination may cause serious side effects or fail to improve outcomes.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.